After 8 weeks of alectinib treatment, ALK-fusion-positive cells in the patient’s mediastinal lymph nodes decreased but ALK fusion-negative malignant cells increased in the pleural effusion (Figure 4K). This evidence concerns the gene ALK and Pleural effusion.